跳至主要内容
临床试验/NCT04083560
NCT04083560已完成不适用

A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment

Sitaram Bhartia Institute of Science and Research2 个研究点 分布在 2 个国家目标入组 708 人开始时间: 2018年9月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
708
试验地点
2
主要终点
Infant neurodevelopment

研究概览

简要总结

Supplementation with Iron and folate have been part of a worldwide strategy targeting anaemia and neural tube defects for many years. However, vitamin B12 deficiency has received much less attention. High prevalence of deficiency in mothers in the antenatal period and in their infants, has been documented. Multiple case series document the neurological consequences of severe deficiency and their reversal with B-12. Trials on the subject are limited and those available have either used an ineffective dose or for a short duration.

Therefore, we propose this randomised controlled trial to compare the efficacy of two different doses (pharmacological and preventive) of maternal Vitamin B-12 supplementation in improving infant B12 deficiency and neurodevelopment. We propose to undertake a multi-centric trial in India and Nepal given the high prevalence of deficiency reported from these countries and to allow a wider socio-demographic spectrum (Pay-for-service hospital catering to middle income populace from India and a free-care public hospital catering to lower income groups from Nepal). We will recruit 720 vegetarian, pregnant women from the antenatal clinics of the Indian and Nepalese centres at their first antenatal visit. Elderly primi mothers, taking B12 supplementation, multiple gestations, chronic medical conditions, anticipating moving out of the city, treated for infertility or with known psychological illnesses will be excluded. In Stage 1, recruited mothers will be randomized into 2 equal groups (360 each). Group 1-Daily 250 μg Vitamin B12 supplementation. Group 2-Daily 50 μg Vitamin B12 supplementation. B-12 will be started in 1st trimester and continue up to 6 months post-partum. In Stage 2, the birth and post-delivery course of the new-born will be monitored and documented for any morbidity. At 9 months, the neurodevelopmental, complementary feeding and home environment will be assessed and infant B12 status will be determined.

The two groups will be compared for the primary (neurodevelopment) and secondary outcomes (biochemical parameters in mother and infant). The results of this study will be used to generate scientific evidence on whether B-12 should be supplemented in vegetarian pregnant women with a view to preventing B-12 deficiency and its neurodevelopmental consequences in the infant.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • <12 weeks gestation
  • Vegetarian mothers

排除标准

  • Mothers already on B12 supplementation
  • Women with multiple gestation, those diagnosed with chronic medical conditions (diabetes mellitus, hypertension, heart disease, neurological disease or thyroid disease), and those who tested positive for hepatitis B, HIV or syphilis (associated with prematurity, IUGR and other neonatal morbidities which could influence neurodevelopment)
  • Women who anticipate moving out of the city before/ after delivery
  • Women treated for infertility
  • Women with known psychological illnesses including depression

研究组 & 干预措施

Intervention group

Experimental

Group A Intervention: 360 pregnant women will receive 250 mcg of B-12 daily orally from 1st trimester to 6 months postpartum

干预措施: Vit B12 (Drug)

Control group

Active Comparator

Group B- Control: 360 pregnant women will receive 50 mcg of B-12 daily orally from 1st trimester to 6 months post partum

干预措施: Vit B12 (Drug)

结局指标

主要结局

Infant neurodevelopment

时间窗: 9 Month of infant age

Developmental Assessment Scale for Indian Infant (modified Bayleys scale) measured as average of motor and mental scores

次要结局

  • Biochemical B12 status of infant(9 months of infant age)
  • Biochemical B12 status of mother(At recruitment)

研究者

发起方
Sitaram Bhartia Institute of Science and Research
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Jitender Nagpal

Senior Consultant and Head of the Department

Sitaram Bhartia Institute of Science and Research

研究点 (2)

Loading locations...

相似试验